Pharmaceuticals
Commercializing and developing pharmaceuticals addressing large unmet needs
Improving the lives of people suffering from mental illness and substance use disorders
Developing improved pharmaceuticals based on innovative drug delivery technologies
Providing evidence-based digital therapies to improve treatment outcomes
What we do
Digital Therapeutics
Product portfolio of scientifically proven digital therapies
Mental illness & substance use disorders
Focusing on areas of great human suffering with wider societal implications
We Care
Shedding light on lives affected by addiction and the road to recovery
September 13-19 2021, is the OPIOID AND HEROIN AWARENESS WEEK. In our latest blog, we share a woman´s moving story about how she struggled with addiction until she found the inner strength and right treatment to turn her life around.
Key News
AUGUST 30, 2021
Synthetic opioids drive record-high surge in fatal overdoses
JULY 16, 2021
Our overdose rescue medication OX124 enters pivotal study
JULY 15, 2021
Announcement of the Q2 2021 Interim Report
Orexo Social
@OrexoABpubl
21 September 2021
WE ARE HIRING. #orexo is a pioneer in bringing together traditional LIFE SCIENCE with TECH-knowledge. Join our exci… https://t.co/lTaVm9M6l3
@OrexoABpubl
17 September 2021
“One day I woke up and the leaves on the tree were a lot greener than they’d ever been” IN OUR LATEST BLOG, Marguer… https://t.co/XsBbbOAkFQ
@OrexoABpubl
16 September 2021
Joseph R Volpicelli Ph.D of Psychiatry visiting @thatsoberguypodcast and among others he talks about how DTx and vo… https://t.co/EGLrcckUFf
Our history
Strong history paving the way for the future. Learn more about our key milestones since we where founded in Uppsala, Sweden, in 1995.
News Flow
Press Releases & News
Synthetic opioids drive record-high surge in fatal overdoses
Orexo’s flagship pharmaceutical pipeline asset OX124 enters pivotal trial
Orexo signs commercial partnership agreement with Sober Grid allowing community users access to clinically proven digital therapies vorvida® and deprexis®
Sober Grid Users to Gain Access to Clinically Proven Digital Therapeutics Through New Commercial Partnership with Orexo
Financial Snapshot
Group net revenues
585 MSEK
LTM1
Group EBITDA
-76 MSEK
LTM1
US Pharma segment EBIT
295 MSEK
LTM1
Cash position
680 MSEK
Q2 2021
1 Last Twelve Months, Q320-Q221, for more information about financial development Link